REal world experieNce with BRIUMVI® (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study (ENABLE)
This observational study is to learn more about the safety, effectiveness, and treatment experience of patients prescribed BRIUMVI® (ublituximab-xiiy).
Why this Research Matters
Multiple sclerosis (MS) is a disease where the body's immune system attacks the brain and spinal cord. Common symptoms are fatigue, numbness or tingling, muscle stiffness or lack of strength, and trouble walking. The information from this study will help us learn more about patients who have been diagnosed with MS and who have been prescribed BRIUMVI® therapy. If you join this study, data will be collected from routine patient care visits for 192-week period as long as you are receiving BRIUMVI®. Participants will also be asked to complete additional research related activities throughout the study.
Who can Participate
You may be able to join the study if you are an adult older than 18 years old with a confirmed relapsing form of MS diagnosis and have been prescribed with BRIUMVI® (ublituximAB-xiiy), but have not yet received the first infusion.
Study ID
Protocol Number: 24-1074
More information available at ClinicalTrials.gov: NCT06433752
Meet the Team
Principal Investigator